- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05027815
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS) (regARDS)
May 8, 2023 updated by: Jeffrey Bluestone
A Phase 1/2a Study of Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells (cePolyTregs) for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With SARS-CoV-2 Infection (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially can reduce lung inflammation, promote lung tissue repair, and significantly improve clinical outcomes.
This trial is to evaluate the impact of a single IV dose of cePolyTregs given to ARDS patients with COVID-19 inflammatory syndrome.
Study Overview
Status
Terminated
Intervention / Treatment
Detailed Description
Tregs are a subset of CD4+ T cells that function to maintain immune system balance.
The function of Tregs in maintaining immune tolerance can be harnessed through Treg cell therapy for treating various immunological diseases.
Adoptive Tregs therapies have been shown to be effective in dozens of animal models, including models of virus-induced ARDS.
This is a Phase 1 study to evaluate the safety and tolerability of cePolyTregs in subjects with ARDS associated with SARS-CoV-2 infection.
The study is an open-label Phase 1 study to assess escalating doses of cePolyTregs administered as a single IV dose.
The study will include up to 3 cohorts of 3 to 6 subjects/cohort followed for a total of 12 weeks.
All subjects will receive standard of care treatment for COVID-19, including dexamethasone per institutional guidelines and other approved therapies for ARDS associated with SARS-CoV-2 infection per institutional guidelines.
Study Type
Interventional
Enrollment (Actual)
7
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27514
- University of North Carolina
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 68 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Diagnosis of ARDS and respiratory failure requiring mechanical ventilation for less than 72 hours at the time of enrollment
- PaO2/FiO2 < 300 and PEEP > 5
- Male or female, age 18 to 70 years at Screening
- Weight > 40 kg
- Documented diagnosis of infection with SARS-CoV-2 virus by PCR
- Chest imaging (radiograph or CT scan) with abnormalities consistent with COVID-19 pneumonia that could not be explained by effusions, pulmonary collapse, or nodules; and respiratory failure that could not be explained by cardiac failure or fluid overload
- Females of childbearing potential and males must use effective contraception practices from Screening until 28 days after the EOS visit
- Females of childbearing potential must have a negative pregnancy test at Screening and within 24 hours prior to dosing of study drug
- Able to provide Informed Consent, either by self or by medical proxy
- Willing and able to comply with this protocol for the entire duration of the study
Exclusion Criteria:
- Any history or sign of significant chronic active or recurrent infection or screening laboratory evidence consistent with a significant chronic active or recurrent infection requiring treatment with antibiotics, antivirals or antifungals (other than SARS-CoV-2); ongoing antimicrobial treatments will not be exclusionary if, in the opinion of the investigator, no active infection is present (other than SARS-CoV-2)
- Receiving extracorporeal membrane oxygenation therapy
- Moribund patients not expected to survive 24 hours after enrollment based on clinical assessment
- History of significant underlying pulmonary disease (requiring home oxygen), renal disease (requiring dialysis for chronic kidney disease), hepatic disease (Child-Pugh score ≥ 7), or known history of cirrhosis.
- Known or suspected immunodeficiency disease
- Positive serology for HBV, HCV, or HIV at Screening
Abnormal CBC defined by:
- Platelet count < 75,000/mm3
- White blood cell count < 2500/mm3
- Absolute neutrophil count < 500/mm3
- History of bone marrow or stem cell transplantation
- Received any type of live attenuated vaccine < 1 month prior to Screening or is planning to receive any such live attenuated vaccine over the course of the study
- History of lung cancer or any other malignancy requiring active treatment, except adequately treated basal cell carcinoma or in situ carcinoma of the uterine cervix
- Any female who is pregnant or breastfeeding, or any female who is planning to become pregnant during the study and follow-up period
- Any condition that, in the investigator's opinion, may compromise study participation, present a safety risk to the subject, or may confound the interpretation of the study results
- A QT duration corrected for heart rate by Fridericia's formula (QTcF) > 450 millisecond (msec) for males or > 470 msec for females, based on either single or averaged QTcF values of triplicate ECGs obtained over a 3-minute interval
- Currently enrolled in another investigational device or drug study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: cePolyTregs 100 x10^6 cells Open Label
single dose of 100 x 10^6 cells by IV infusion
|
cryopreserved cellular therapy product in cryostor CS5, for IV infusion
Other Names:
|
Experimental: cePolyTregs 200 x10^6 cells Open Label
single dose of 200 x 10^6 cells by IV infusion
|
cryopreserved cellular therapy product in cryostor CS5, for IV infusion
Other Names:
|
Experimental: cePolyTregs 400 x10^6 cells Open Label
single dose of 400 x 10^6 cells by IV infusion
|
cryopreserved cellular therapy product in cryostor CS5, for IV infusion
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs)
Time Frame: 28 days post infusion
|
DLT is defined as any related treatment-emergent adverse event (TEAE) with a National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI CTCAE 5.0) grade ≥ 3 which also represents a shift from baseline clinical status of ≥ 1 NCI CTCAE grade
|
28 days post infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Chair: Maor Sauler, MD, Yale University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 23, 2021
Primary Completion (Actual)
March 2, 2022
Study Completion (Actual)
March 2, 2022
Study Registration Dates
First Submitted
August 26, 2021
First Submitted That Met QC Criteria
August 26, 2021
First Posted (Actual)
August 30, 2021
Study Record Updates
Last Update Posted (Actual)
June 5, 2023
Last Update Submitted That Met QC Criteria
May 8, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Respiration Disorders
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- Disease
- Infant, Newborn, Diseases
- Lung Injury
- Infant, Premature, Diseases
- COVID-19
- Syndrome
- Respiratory Distress Syndrome
- Respiratory Distress Syndrome, Newborn
- Acute Lung Injury
Other Study ID Numbers
- UCSF-cePolyTregs-01
- 3UM1AI109565-08S3 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
-
Sinovac Life Sciences Co., Ltd.RecruitingInfection of Upper Respiratory Tract Caused by 2019-nCoVChina
-
Central Hospital, Nancy, FranceRecruitingRespiratory Compliance | ARDS Due to Disease Caused by SARS Co-V-2 | Sequels of COVIDFrance
-
Vanderbilt University Medical CenterRecruitingCovid19 | Pulmonary Fibrosis | Sars-CoV-2 Infection | COVID-19 Acute Respiratory Distress Syndrome | Dyspnea Caused by 2019-nCoVUnited States
-
Hospital Universitario Ramon y CajalRecruitingCOVID-19 Acute Respiratory Distress Syndrome | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2Spain
-
Kepler University HospitalCompletedARDS Due to Disease Caused by SARS Co-V-2Austria
-
The First Hospital of Jilin UniversityCompletedARDS Due to Disease Caused by SARS Co-V-2China
-
Pomeranian Medical University SzczecinNot yet recruitingOxygen Deficiency | Corona Virus Infection | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2Poland
-
Hopital of MelunCompletedCOVID-19 Pneumonia | ARDS Due to Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2France
-
Leidos Life SciencesUnited States Department of DefenseActive, not recruitingCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV InfectionUnited States
-
Leidos Life SciencesUnited States Department of DefenseWithdrawnCOVID-19 | Covid19 | Coronavirus Disease 2019 | SARS-CoV-2 Infection | SARS-CoV-2 Acute Respiratory Disease | COVID-19 Pandemic | COVID-19 Virus Infection | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease | 2019-nCoV Infection
Clinical Trials on Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
-
National Institute of Allergy and Infectious Diseases...Autoimmunity Centers of ExcellenceTerminatedLupus Erythematosus, Systemic | Lupus Erythematosus, Cutaneous | Lupus Erythematosus, DiscoidUnited States
-
University of AlbertaJuvenile Diabetes Research Foundation; Diabetes Research Institute Foundation; Alberta Diabetes Institute and other collaboratorsActive, not recruiting
-
University of California, San FranciscoNational Institute of Allergy and Infectious Diseases (NIAID); Juvenile Diabetes...CompletedType 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...Rho Federal Systems Division, Inc.; Autoimmunity Centers of ExcellenceTerminatedPemphigus Vulgaris | Pemphigus FoliaceusUnited States
-
Everett MeyerNational Cancer Institute (NCI)WithdrawnGraft Versus Host DiseaseUnited States
-
Masonic Cancer Center, University of MinnesotaTerminatedLymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host DiseaseUnited States
-
University of FloridaUnited States Department of Defense; AM Rosen FoundationRecruitingGlioblastoma | Glioblastoma MultiformeUnited States
-
Imcyse SATerminatedMultiple Sclerosis, Relapsing-RemittingBelgium
-
Xijing HospitalBeijing GD Initiative Cell Therapy Technology Co., Ltd.Not yet recruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)Active, not recruiting